Abstract:
Objective To investigate the relationship between the expression levels of serum 25 hydroxyvitamin D (25(OH)D), fibroblast growth factor 19 (FGF19) and delivery outcome in patients with gestational diabetes mellitus (GDM).
Methods A total of 98 GDM patients hospitalized and delivered in our hospital from January 2021 to January 2022 were regarded as the study group, and 90 healthy pregnant women who came to our hospital for prenatal examination and delivery were included as the control group at the same time, and the general data of the two groups were compared. Fasting blood glucose (FPG) and 2h postprandial blood glucose (2h PG) were measured by glucose oxidase method. Enzyme linked immunosorbent assay (ELISA) was used to detect the levels of serum 25(OH)D and FGF19 in the two groups. The study group was divided into poor outcome group (22 cases) and good outcome group (76 cases) according to whether there was adverse delivery outcome, logistic regression model was used to analyze the related influencing factors of adverse delivery outcome, the predictive value of serum 25(OH)D and FGF19 levels for adverse delivery outcomes in GDM patients was analyzed by ROC curve.
Results Compared with the control group, the serum levels of 25 (OH) D and FGF19 in the study group decreased (P < 0.05), while FPG and 2-hour PG increased (P < 0.05). Compared with the group with good outcomes, the serum levels of 25 (OH) D and FGF19 in the group with poor outcomes decreased (P < 0.05). Logistic regression analysis showed that serum 25(OH)D and FGF19 levels were protective factors for the delivery outcome of GDM pregnant women (P < 0.05). The area under the curve of serum 25(OH)D and FGF19 in predicting the delivery outcome of GDM patients was 0.955 and 0.892, respectively. The truncation value was 37.35 nmol/L and 95.60 ng/L, respectively. The sensitivity was 81.82% and 72.73%, respectively. The specificity was 96.05% and 93.42%, respectively. The AUC of serum 25(OH)D combined FGF19 levels to predict the delivery outcome of GDM patients was 0.977, the sensitivity was 95.45%, and the specificity was 92.11%.
Conclusion The levels of serum 25(OH)D and FGF19 in GDM patients are decreased, and they are closely related to the delivery outcome.